White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation

Charlotte E. Teunissen, Markus Otto, Sebastiaan Engelborghs, Sanna Kaisa Herukka, Sylvain Lehmann, Piotr Lewczuk, Alberto Lleó, Armand Perret-Liaudet, Hayrettin Tumani, Martin R. Turner, Marcel M. Verbeek, Jens Wiltfang, Henrik Zetterberg, Lucilla Parnetti, Kaj Blennow

    Research output: Contribution to journalReview articleResearchpeer-review

    17 Citations (Scopus)

    Abstract

    © 2018 The Author(s). Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer's disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. We still, however, have a strong need for additional biomarkers and several gaps in their development and implementation should be filled. Examples of such gaps are i) limited knowledge of the causes of neurological diseases, and thus hypotheses about the best biomarkers to detect subclinical stages of these diseases; ii) the limited success translating discoveries obtained by e.g. initial mass spectrometry proteomic low-throughput studies into immunoassays for widespread clinical implementation; iii) lack of interaction among all stakeholders to optimise and adapt study designs throughout the biomarker development process to medical needs, which may change during the long period needed for biomarker development. The Society for CSF Analysis and Clinical Neurochemistry (established in 2015) has been founded as a concerted follow-up of large standardisation projects, including BIOMARKAPD and SOPHIA, and the BioMS-consortium. The main aims of the CSF society are to exchange high level international scientific experience, to facilitate the incorporation of CSF diagnostics into clinical practice and to give advice on inclusion of CSF analysis into clinical guidelines. The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society.
    Original languageEnglish
    Article number30
    JournalAlzheimer's Research and Therapy
    Volume10
    Issue number1
    DOIs
    Publication statusPublished - 15 Mar 2018

    Keywords

    • Assay development
    • Biomarker discovery
    • Body fluids
    • Cerebrospinal fluid
    • Clinical implementation
    • Education Biomarkers
    • Neurology
    • Society

    Fingerprint Dive into the research topics of 'White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation'. Together they form a unique fingerprint.

  • Cite this

    Teunissen, C. E., Otto, M., Engelborghs, S., Herukka, S. K., Lehmann, S., Lewczuk, P., Lleó, A., Perret-Liaudet, A., Tumani, H., Turner, M. R., Verbeek, M. M., Wiltfang, J., Zetterberg, H., Parnetti, L., & Blennow, K. (2018). White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 10(1), [30]. https://doi.org/10.1186/s13195-018-0359-x